OasisLMS

This 90-minute virtual course will explore the latest guideline-concordant care for managing patients with metastatic prostate cancer, including germline and somatic biomarker testing, integrating genetic and biomarker test results into routine clinical workflows, selecting PARP inhibitor-based combination therapies and collaborating with multidisciplinary care teams to implement testing pathway and managing adverse events associated with targeted combination therapy.

This live virtual course will offer simultaneous translation in 60+ languages. Powered by an involved AI based technology, Wordly, attendees will be able to access the audio and captioning translations in real time to help make the course more accessible to our colleagues around the globe.

• AstraZeneca

• Urologists
• Fellows
• Residents

After participating in this CME activity, participants will be able to:

• Apply updated AUA guideline–concordant recommendations for germline and somatic biomarker testing (including HRR mutations such as BRCA and non-BRCA) when evaluating patients with metastatic prostate cancer at key clinical decision points.
• Integrate evidence-based strategies for ordering, interpreting, and acting on biomarker and genetic test results in routine clinical workflows across practice settings during initial and subsequent treatment planning.
• Evaluate the mechanism of action and clinical rationale for PARP inhibitor–based combination therapies when selecting treatment options for patients with mHSPC and mCRPC at the time of therapy initiation.
• Incorporate current efficacy and safety data for PARP inhibitor combinations into treatment sequencing decisions for patients with metastatic prostate cancer during real-world clinical management over the next 6–12 months.
• Collaborate with multidisciplinary care teams to implement testing pathways and manage adverse events associated with targeted therapy combinations in diverse practice settings during ongoing patient care.

Education Council Disclosures

Education Council Disclosures (2026)

COI Work Group Disclosures

COI Work Group Disclosures (2026)

Faculty Disclosures 
To be added prior to course.

AUA Office of Education Staff has nothing to disclose.
All relevant financial replationships have been mitigated.

ACCREDITATION: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: The American Urological Association designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit^TM.

EVIDENCE BASED CONTENT: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA COMMITTMENT: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress. 

REPORTING HARRASSMENT: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly. 

The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy. 

DISCLAIMER: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA). 

CONSENT TO USE PHOTOGRAPHIC IMAGES: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. 

AUDIO, VIDEO, PHOTOGRAPHIC EQUIPMENT: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.